Report of the committee
Friday, June 10, 2016
The Standing Senate Committee on Legal and Constitutional Affairs has the honour to present its
SIXTH REPORT
Your committee, to which was referred Bill S-225, An Act to amend the Controlled Drugs and Substances Act (substances used in the production of fentanyl), has, in obedience to the order of reference of May 12, 2016, examined the said bill and now reports the same with the following amendment:
1. Clause 1, page 1: Replace lines 8 to 10 with the following:
26 1-Phenethyl-4-piperidone and its salts
27 4-Piperidone and its salts
28 Norfentanyl (N-phenyl-N-piperidin-4-ylpropanamide) and its salts
29 1-Phenethylpiperidin-4-ylidenephenylamine and its salts
30 N-Phenyl-4-piperidinamine and its salts
Your committee has also made certain observations, which are appended to this report.
Respectfully submitted,
BOB RUNCIMAN
Chair
Observations
to the Sixth Report of the Standing Senate Committee on Legal and Constitutional Affairs (Bill S-225)
1. The committee encourages Health Canada to launch a public campaign on the dangers of opioids, in particular fentanyl.
2. The committee encourages Health Canada to streamline the process by which substances are assessed to determine if they ought to be regulated under the Controlled Drugs and Substances Act in order to ensure a rapid response to the known dangers of substances such as fentanyl.